

Poultry Gastrointestinal-derived Lactic Acid Bacteria (pGIT-d-LAB) Inhibit Multiple Antibiotics Resistance Bacterial and Fungal Pathogens

Bolanle Adeniyi ^{1*}, Abimbola Adesuyi ¹, Funmilola Ayeni ¹, Temitope Ogunbanwo ² and Taiwo Agidigbi ¹

1. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria

2. Department of Microbiology, Faculty of Science, University of Ibadan, Ibadan, Nigeria

Abstract

Background: To develop a probiotic formulation for poultry feed, a few poultry gastrointestinal derived lactic acid bacteria (pGIT-d-LAB) were isolated from chicken intestinal specimens and *in vitro* experiment was performed to evaluate their efficacy as potential probiotic candidate.

Methods: A total of 6 strains of LAB: *Lactobacillus brevis* (*L. brevis*), *Lactobacillus acidophilus* (*L. acidophilus*), *Lactobacillus casei* (*L. casei*), *Pediococci* spp, *Lactobacillus fermentum* (*L. fermentum*) and *Lactobacillus plantarum* (*L. plantarum*) were isolated and cultured for collection of Cell Free Supernatant (CFS). CFS collected was tested against pathogenic bacterial isolated from chicken feces as well as prevalent fungal pathogens, utilizing agar-well diffusion techniques. A preliminary investigation into the susceptibility of the pathogens to diverse antibiotics and antifungal drugs was conducted. Bacterial pathogens exhibiting resistance to a minimum of three classes of antibiotics were subsequently identified for pGIT-d-LAB CFS screening.

Results: The observed results revealed that the CFS derived from the isolates exhibited varying degrees of growth inhibition against different pathogens. Among the tested pGIT-d-LAB isolates, *L. acidophilus* demonstrated the most prominent zone of inhibition, measuring 18 mm against *Klebsiella pneumoniae* ZTAC 1233. Notably, *Citrobacter diversus* ZTAC 1255 showed resistance to all tested pGIT-d-LAB. Quantification of the metabolites produced was performed, and peak production levels was determined. *L. acidophilus* produced the highest amount of lactic acid (1.789g/l), *Pediococci* spp. produced the highest amount of diacetyl and H₂O₂ (1.918g/l) (0.0025g/l) at 48 hr peak values respectively.

Conclusion: The test isolates are potential probiotic candidates for controlling pathogens in poultry.

Keywords: Anti-bacterial agents, Chickens, Lactic acid, Poultry, Probiotics

To cite this article: Adeniyi B, Adesuyi A, Ayeni F, Ogunbanwo T, Agidigbi T. Poultry Gastrointestinal-derived Lactic Acid Bacteria (pGIT-d-LAB) Inhibit Multiple Antibiotics Resistance Bacterial and Fungal Pathogens. Avicenna J Med Biotech 2024;16(2):111-119.

* Corresponding author:

Bolanle Adeniyi, Ph.D.,
Department of Pharmaceutical
Microbiology, Faculty of
Pharmacy, University of Ibadan,
Ibadan, Nigeria

Tel: + 23 48023451480

E-mail:

baadeniyi@yahoo.co.uk

Received: 23 Aug 2023

Accepted: 25 Nov 2023

Introduction

Lactic Acid Bacteria (LAB) are a group of bacteria that produce lactic acid as a byproduct of their metabolism. They are Gram-positive, non-spore-forming bacteria and are commonly found in various environments, including plants, animals, fermented food products and the human gastrointestinal tract ^{1,2}. Their antimicrobial properties, ability to modulate the immune system, and capacity to inhibit the growth of pathogens make them promising candidates for managing infections ¹⁻³. Some of the most well-known genera of lactic acid bacteria include *Lactobacillus*, *Propionibacterium*, *Streptococ-*

cus, *Bifidobacterium*, *Pediococcus*, *Leuconostoc*, and *Lactococcus* ¹⁻³. These genera encompass numerous species and strains that have different characteristics and are employed in various industrial and commercial applications ⁴⁻⁶. They are generally considered safe for human consumption and are often referred to as probiotics due to their potential health benefits ^{6,7-9}.

Probiotics are live micro-organisms that confer health benefits when consumed in adequate amounts. LAB can help maintain a healthy balance of micro-organisms in the gut and contribute to digestion, nutri-

ent absorption, and immune function⁹⁻¹². Additionally, LAB have antimicrobial properties that can inhibit the growth of harmful bacteria, making them useful in food preservation and the prevention of foodborne illnesses^{6,9,13-16}. Their diverse metabolic capabilities and beneficial properties make them a significant group of bacteria in both scientific and industrial contexts^{17,18}.

In the context of bacterial infections, LAB exerts their antimicrobial effects through multiple mechanisms. LAB can produce organic acids such as lactic acid and acetic acid, which lower the pH of their environment, creating an inhospitable environment for many pathogenic bacteria^{9,11,12,19}. LAB can produce bacteriocins, which are antimicrobial peptides that selectively target and inhibit the growth of other bacteria. These mechanisms contribute to the competitive exclusion of pathogens and the maintenance of a balanced microbial ecosystem²⁰⁻²³.

Furthermore, LAB's role in managing fungal infections has also been explored²⁴⁻²⁹. Certain strains of LAB have demonstrated the ability to inhibit the growth of various fungal pathogens through competitive exclusion, production of antifungal compounds, and modulation of the host's immune response^{29,30}. LAB's potential to counter fungal infections is particularly significant, given the rising concern of antifungal resistance and the limited treatment options available. Probiotics have demonstrated encouraging potential in both the prevention and treatment of allergic conditions, encompassing disorders like atopic dermatitis and allergic rhinitis^{31,32}. Probiotics hold clinical significance in the realm of gastrointestinal disorders, spanning conditions such as irritable bowel syndrome, diarrhea, inflammatory bowel disease, and antibiotic-associated diarrhea³¹⁻³⁶. Metabolic disorders have attained a widespread epidemic status on a global scale, search for probiotics for management of disease including but not limited to obesity, diabetes, and non-alcoholic fatty liver disease is on increased³⁰⁻³⁹.

The primary objective of this study was to isolate, characterize, and evaluate pGIT-d-LAB strains possessing probiotic attributes from poultry chicken. These strains were intended for potential use as a supplements or alternative to antibiotics in the context of poultry infection control and management.

Materials and Methods

Poultry sample collection and preparation

Thirty³⁰ intestinal fecal samples were collected randomly from broilers in a commercial poultry farm in Ibadan, southwestern Nigeria for the isolation of poultry gastrointestinal-derived lactic acid bacteria (pGIT-d-LAB). Sample bottles and test tubes containing 5 ml sterile peptone water were labeled accordingly after transporting samples into the laboratory. The workbench was disinfected by cleaning with 70% ethanol, and a loopful of each sample was then added into 5 ml

of sterile peptone water and incubated aerobically at 37°C for 24 hr.

Isolation, identification, and characterization

Serial dilutions of the cultures from the peptone water were then performed according to method described with slight modification^{13,40}. Pour plate method was used for the isolation of the isolates by transferring 0.1 ml of selected dilution aseptically into the sterile plates containing de Man Rogosa Sharpe agar (for isolation of LAB) and various media were used to isolate bacterial species. The plates were incubated micro-aerobically at 37°C (Oxoid: Campygen, UK) after which pure colonies were isolated. Identification and characterization of isolates were carried out according to conventional microbiological standard practices (macroscopic, microscopic, physiological, and biochemical tests).

Antibiotic susceptibility test

Antibiotic susceptibility test for each bacterial pathogen was performed using the disc diffusion method. 0.1 ml of actively growing bacterial culture containing approximately 1×10^6 cfu/ml compared to McFarland standard was inoculated into Mueller Hinton agar by pour plate method. Different antibiotic sensitivity-discs such as Nitrofurantoin 300 µg, Nalidixic acid 30 µg, Ofloxacin 30 µg, Augmentin 30 µg, Tetracycline 30 µg, Chloramphenicol 30 µg, Amoxicillin 25 µg, Gentamicin 10 µg, Clotrimazole 5 µg, Erythromycin 5 µg and Cloxacillin 5 µg were placed on the solidified agar surface. For fungal isolates, itraconazole and Griseofulvin were used as positive control. The plates were incubated aerobically at 37°C for 24 hr. After 24 hr, the diameter of the zone of inhibition of each disc was measured. The zone of inhibition corresponds to the antibiotic activity of each disc. The relative susceptibility of each isolate to each antibiotic was shown by a clear zone of inhibition resistance was defined by the absence of a zone of inhibition or inhibition less than 10 mm in diameter.

Determination of in vitro antimicrobial activity

Cell Free Supernatants (CFS) of pGIT-d-LAB isolates were obtained from MRS broth cultures after 72 hr incubation at 30°C by centrifugation at 10,000×g for 10 min at 4°C. The inhibitory activities of the CFS against the pathogenic bacteria and fungal were assayed by the agar well diffusion tests. The plates were incubated at 37°C for 24 hr after which clear zones were examined around the wells. The antimicrobial effects were recorded by measuring the zone of inhibition around the well.

Quantitative determination of antimicrobial compounds produced by pGIT-d-LAB

For this measurement, the test organisms were grown in MRS broth for 72 hr and samples collected at 12 hr interval up to 72 hr and centrifuged at 3,000×g for 15 min to obtain supernatant.

Lactic acid

Lactic acid production was determined slight modification to the method described⁴¹ by titrating 25 ml of the supernatant fluid of the test organism and adding three drops of phenolphthalein as indicator. 0.1 M NaOH was slowly added from a burette onto the samples until a pink colour appeared. Each ml of 0.1 M NaOH is equivalent to 90.08 mg of lactic acid.

Hydrogen peroxide (H₂O₂)

Twenty (20) ml of 0.1 M diluted tetraoxosulphate (VI) acid was added to 25 ml of the supernatant fluid of the test organism. Titration was carried out with 0.1 M potassium permanganate (KMnO₄). Each ml of 0.1 M potassium permanganate is equivalent to 1.79 mg of H₂O₂ solution. Decolourization of the sample was regarded as the end point. The volume of H₂O₂ produced was then calculated⁴².

Diacetyl

This was determined by transferring 25 ml of the supernatant fluid of the test organism into 100 ml flask and 7.5 ml of hydroxylamine solution was used for the residual titration. The flasks were titrated with 0.1 M HCL to a greenish yellow end point using bromophenol red as indicator. The equivalent factor of HCL to diacetyl is 21.5 mg. The concentration of diacetyl produced was calculated according to the method of food chemical codex⁴³.

Data analysis

All data were replicated and expressed as means ± SEM (standard error of the mean) using student t-test one-way ANOVA (analysis of variance) on Microsoft excel sheet. Graphical representation was performed using software GraphPad Prism9 (GraphPad software Inc., San Diego, USA).

Results

The occurrence of common pathogenic bacterial spp. in poultry feces

A total of 25 pathogenic bacteria were isolated from the fecal samples of chicken (Figure 1). The isolates were subjected to standard microbiological and biochemical tests to identify the bacteria species.

Among the 25 microorganisms identified, the distribution is as follows: *Escherichia coli* (*E. coli*) (5), *Pseudomonas* spp. (5), *Klebsiella pneumonia* (3), *Bacillus subtilis* (*B. subtilis*) (3), *Micrococcus virians* (*M. virians*) (3), *Mycobacterium* spp. (2), *Salmonella typhi* (2), *Citrobacter freundii* (1) and *Citrobacter diversus* (*C. diversus*) (1) (Figure 1A). In overall, result of the prevalence of bacteria pathogens in the feces of chicken shows higher percentage of prevalence with *E. coli* and *Pseudomonas* spp. (20%) followed by *Klebsiella* and *Bacillus* (12%), *Mycobacterium* spp. and *Lactobacillus delbrueckii* (8%), while the genus *Citrobacter* spp. (4%) showed the lowest prevalence (Figure 1B).




Figure 1. A) The occurrence and B) proportional percentage of pathogenic bacteria from chicken intestine.




Figure 2. A) The occurrence and B) proportional percentage of pGIT-d-LAB isolated from intestine.

Occurrence of LAB spp. in poultry intestinal feces

Following standard procedures for isolation and identification, a total of 30 strains of LAB were isolated from chicken intestine. The isolates were identified as *Lactobacillus brevis* (*L. brevis*)¹⁴, *Lactobacillus plantarum* (*L. plantarum*)⁷, *Lactobacillus acidophilus* (*L. acidophilus*)⁵, *Pediococcus* spp.², *Lactobacillus casei* (*L. casei*)¹, and *Lactobacillus fermentum* (*L. fermentum*)¹ (Figure 2A). The percentage occurrence of pGIT-d-LAB from the chicken intestine was found to be *L. brevis* (46.66%), followed by *L. plantarum* (23.33%), and *L. acidophilus* (16.66%), while *L. casei* and *L. fermentum* both have (3.33%), respectively. The varying percentages of occurrence of pGIT-d-LAB isolates indicate a wide distribution of LAB strains in the intestines of chicken (Figure 2B).

Antibiogram assay

The sensitivity of the different pathogenic bacteria to commercial standard available antibiotics sensitivity disc containing known concentration of antibiotics was investigated. All Gram-negative bacteria showed susceptibility to chloramphenicol except *M. vivian's* ZTCC 125. Also, all Gram-positive bacteria showed susceptibility to clotrimazole except *Bacillus subtilis* ZTAC 1247, *Mycobacterium* spp. ZTCC 1250, and *M. vivians* ZTCC 1251. All the pathogenic bacteria demonstrated resistance to Amoxicillin, Augmentin, and Tetracycline, Erythromycin and Cloxacillin. All the Gram-negative bacteria showed resistance to Nalidixic

acid except *E. coli* ZTCC 1241 and *E. coli* ZTCC 1242 which showed intermediate susceptibility. All Gram-positive bacteria demonstrated resistance to Amoxicillin, Erythromycin, Cloxacillin, Augmentin and Tetracycline. In general, all the bacteria pathogens demonstrated multiple drug resistance as defined as resistance to at least two different classes of antibiotics (Table 1). The use of antimicrobial agents such as antibiotics as a preventive or control measure of poultry diseases has given rise to the extensive evolution of antimicrobial resistance among pathogenic bacteria. Most of these pathogens might also be Extended Spectrum Beta-Lactamase (ESBL) producers which are global health concerns and major problems for the treatment of different infections caused by *Enterobacteriaceae* ^{44,45}.

pG IT-d-LAB exhibit antagonist action against multiple antibiotics resistance bacterial

The CFS of the pGIT-d-LAB isolates produced antagonistic activities against all the pathogenic bacteria in this study except *Citrobacter diversus* ZTAC 1255. The widest zone of inhibition of 18 mm in diameter was produced by *L. acidophilus* against *Klebsiella pneumoniae* (K. pneumoniae) ZTAC 1233 and *L. casei* against *Citrobacter freudi* ZTAC 1249. The lowest zone of inhibition of 9 mm in diameter was produced by *L. plantarum* against *Pseudomonas* spp. ZTAC 1252. The CFS of *L. brevis*, *L. acidophilus* and *L. casei* also showed inhibitory activity against *K. pneumoniae*

ZTAC 1233. Metabolites produced by the pGIT-d-LAB isolates showed an impressive antagonistic activity against *Mycobacterium* spp. ZTAC 1236, *M. virians* ZTAC 1235. In addition, it can be observed from the table that none of CFS of the isolates showed activity against *C. diversus* ZTAC 1255 (Table 2).

CFS of pGIT-d-LAB exhibit antagonist action against fungal pathogens

In this study, the CFS of the pGIT-d-LAB isolates produced antagonistic activity against all the selected fungal pathogens except *Candida valida* (*Candida valida*) ZTAC 1409 (Table 3). The largest zone of inhibition (24 mm) was produced by *L. acidophilus* against *Candida albicans* (*C. albicans*) ZTAC 1401. The CFS of the isolate of *L. brevis* was exceptional as it was the only isolate that was able to exhibit antagonistic activity against *Candida tropicalis* (*C. tropicalis*) ZTAC 1403 and *Epidermophyton rubrum* (*E. rubrum*) ZTAC 1411. The CFS of *L. casei* was unable to produce any antagonistic activity against the fungal pathogens. *Trichophyton rubrum* (*T. rubrum*) ZTAC 1407 was the most susceptible dermatophyte to metabolites produced by pGIT-d-LAB isolates. The largest zone of inhibition (17 mm) against the dermatophytes was shown by *Pediococci* against *T. rubrum* ZTAC 1407. *Candida krusei* ZTAC 1405 was inhibited by the CFS of *L. plantarum* (18 mm) and *Pediococci* spp. (21 mm). The CFS of *L. fermentum* did not inhibit *C. tropicalis*

Table 1. Antibigram Showing Drug Resistance and Sensitivity Patterns of Test Bacteria (zone of inhibition in mm)

Pathogenic organisms/antibiotics	AMX	COT	NIT	GEN	NAL	OFL	AUG	TET	CHL	ERY	CXC
<i>Klebsiella pneumonia</i> ZTAC 1233	R	20	10	22	R	32	R	R	R	R	R
<i>B. subtilis</i> ZTAC 1234	R	25	R	20	R	R	R	R	22	R	R
<i>M. virians</i> ZTAC 1235	R	25	R	21	R	R	R	R	21	R	R
<i>Mycobacterium</i> spp. ZTAC 1236	R	23	R	20	R	R	R	R	20	R	R
<i>K. pneumonia subsp. ozaenae</i> ZTAC 1237	R	18	10	15	12	20	R	R	R	R	R
<i>M. virians</i> ZTAC 1238	R	18	R	15	R	R	R	R	10	R	R
<i>E. coli</i> ZTAC 1239	R	20	10	18	R	28	R	R	R	R	R
<i>E. coli</i> ZTAC 1240	R	21	10	16	R	25	R	R	R	R	R
<i>E. coli</i> ZTAC 1241	R	R	10	18	R	38	R	R	R	R	R
<i>E. coli</i> ZTAC 1241	R	15	12	20	16	20	R	R	R	R	R
<i>S. typhi</i> ZTAC 1243	R	20	R	18	R	R	R	R	20	R	R
<i>S. typhi</i> ZTAC 1244	R	20	R	20	R	R	R	R	18	R	R
<i>E. coli</i> ZTAC 1245	R	16	10	18	R	20	R	R	R	R	R
<i>Pseudomonas</i> spp. ZTAC 1246	R	R	R	13	R	15	R	R	R	R	R
<i>B. subtilis</i> ZTAC 1247	R	R	R	18	R	R	R	R	18	R	R
<i>Pseudomonas</i> spp. ZTAC 1248	R	R	R	14	R	16	R	R	R	R	R
<i>Citrobacter freudi</i> ZTAC 1249	R	R	R	16	R	30	R	R	R	R	R
<i>Mycobacterium</i> spp. ZTAC 1250	R	R	R	12	10	R	R	R	11	R	R
<i>M. virians</i> ZTAC 1251	R	R	R	12	R	R	R	R	11	R	R
<i>Pseudomonas</i> spp. ZTAC 1252	R	R	R	12	R	16	R	R	R	R	R
<i>Pseudomonas</i> spp. ZTAC 1253	R	R	R	13	R	15	R	R	R	R	R
<i>Pseudomonas</i> spp. ZTAC 1254	R	R	R	13	R	20	R	R	R	R	R
<i>Citrobacter diversus</i> ZTAC 1255	R	10	R	13	R	18	R	R	R	R	R
<i>B. subtilis</i> ZTAC 1256	R	R	R	18	R	R	R	R	20	R	R
<i>K. pneumonia</i> ZTAC 1257	R	R	R	16	R	30	R	R	R	R	R

Augmentin (30 mg), Tetracycline (30 mg), Nitrofurantoin (300 mg), Chloramphenicol (30 mg), Ofloxacin (30 mg), Nalidixic acid (30 mg), Amoxycillin (25 mg), Clotrimazole (25 mg), Gentamycin (10 mg), Cloxacillin (5 mg), and Erythromycin (5 mg). * Resistance (R) = <10 mm; **Sensitivity = ≥10 mm

Table 2. Activity of LAB against pathogenic bacteria (diameter of zone of inhibition in mm)

LAB isolates	<i>E. coli</i> ZTAC 1241	<i>P. aeruginosa</i> ZTAC 1252	<i>K. pneumoniae</i> ZTAC 1233	<i>B. subtilis</i> ZTAC 1234	<i>M. varians</i> ZTAC 1235	<i>Mycobacterium</i> spp. ZTAC 1236	<i>S. typhi</i> ZTAC 1243	<i>C. diversus</i> ZTAC 1255	<i>C. freudi</i> ZTAC 1249
<i>L. brevis</i>	10±1.0	17±2.0	12±0.0	-	15±1.0	15±0.0	14±1.0	-	13±1.0
<i>L. plantarum</i>	12±0.0	-	10±1.0	10±0.0	15±0.0	17±2.0	-	-	12±0.0
<i>L. acidophilus</i>	10±1.0	10±1.0	18±1.0	-	14±1.0	16±0.0	15±1.0	-	15±0.0
<i>Pediococci</i> spp.	10±1.0	12±1.0	10±2.0	-	13±0.0	15±1.0	13±0.0	-	16±1.0
<i>L. casei</i>	10±1.0	13±0.0	10±2.0	-	16±0.0	14±0.0	-	-	17±2.0
<i>L. fermentum</i>	10±1.0	11±0.0	10±1.0	-	16±1.0	16±0.0	15±1.0	-	14±0.0

* Diameter of the cork borer = 8 mm

Table 3. Activity of LAB against pathogenic fungal (diameter of zone of inhibition in mm)

LAB isolates	Fungal pathogens					
	<i>C. albicans</i> ZTAC 1401	<i>C. tropicalis</i> ZTAC 1403	<i>C. krusei</i> ZTAC 1405	<i>T. rubrum</i> ZTAC 1407	<i>C. valida</i> ZTAC 1409	<i>E. rubrum</i> ZTAC 1411
<i>L. brevis</i>	-	16±1.0	-	15±1.0	-	13±1.0
<i>L. plantarum</i>	23±1.0	-	18 ±1.0	12±1.0	-	-
<i>L. acidophilus</i>	24±0.0	-	-	11±2.0	-	-
<i>Pediococci</i> spp	21±0.0	-	21±0.0	17±1.0	-	-
<i>L. casei</i>	-	-	-	-	-	-
<i>L. fermentum</i>	-	-	-	14±1.0	-	-

* Diameter of the cork borer = 8 mm

ZTAC 1403, *C. albicans* ZTAC 1401, *C. krusei* ZTAC 1405 and *C. valida* ZTAC 1409 (Table 3). In contrast to our finding, Ronnqvist *et al*, 2007⁴⁶ reported that a LAB isolate, *L. fermentum* Ess-1, showed activity against *C. albicans* and *Candida glabrata*. The antagonistic activity of LAB metabolites on the two dermatophytes; *T. rubrum* ZTAC 1407 and *E. rubrum* ZTAC 1411 showed that both were sensitive to the antimicrobial producing LAB to varying degrees except that *E. rubrum* ZTAC 1411 showed susceptibility to the metabolite produced by *L. brevis* only. *T. rubrum* strain ZTAC 1407 displayed the greatest susceptibility among the dermatophytes examined in this research. Among the tested strains, *Pediococcus* spp. exhibited the most potent activity (17 mm) against *T. rubrum* ZTAC 1407. Interestingly, only the CFS generated by *L. casei* showed no impact on the growth of the dermatophyte *T. rubrum* ZTAC 1407. Beyond directly inhibiting fungal growth, LAB also possess the capability to selectively hinder the production of mycotoxins and immobilize mycotoxins by attaching to their surface. The antimicrobial capacity of LAB has been well documented⁶. In general, *Lactobacillus* species were the most inhibitory to test organisms followed by *Pediococci* spp. and *Leuconostoc* spp. (Table 3).

Quantification of metabolites produced by pGIT-d-LAB

Quantitative investigation of three different antimicrobial compounds produced by pGIT-d-LAB species was investigated. We found that metabolites produc-

tion and concentration varied across LAB species (Figure 3-5). In this study, *Pediococci* spp. produced the highest concentration of diacetyl (1.918 g/l) while the lowest concentration was produced by *L. casei* (1.382 g/l) (Figure 3A). The heatmap showed that all the isolates produce the highest concentration of metabolites at 48 hr peak; *L. brevis* 1.701 g/l, *L. plantarum* 1.621 g/l, *L. acidophilus* 1.704 g/l, *Pediococci* spp. 1.918 g/l, *L. casei* 1.382 g/l and *L. fermentum* 1.617 g/l, respectively (Figure 3B).

Among the top producers of lactic acid at 24, 48 and 72 hr, *L. plantarum*, produced 1.644 g/l, 1.707 g/l, 1.482 g/l, *L. acidophilus* produced 1.534 g/l, 1.789 g/l and 1.428 g/l while *L. fermentum* produces 1.535 g/l, 1.715 g/l and 1.628 g/l, respectively (Figure 4A). The production of lactic acid among these isolates was peak at 48 hr, *L. acidophilus* produced highest volume of 1.789 g/l while *L. casei* produced the lowest volume of 1.164 g/l (Figure 4B). H₂O₂ production was also determined among the pGIT-d-LAB isolates. Overall, the concentration of H₂O₂ produced were generally low among all pGIT-d-LAB isolates (Figure 5A). The highest yield was produced by *Pediococci* spp. (0.0025 g/l) and the lowest yield was produced by *L. casei* (0.0014 g/l) after 48 hr incubation (Figure 5B).

Discussion

The continuous alternate search for antibiotics due to development of drug resistance offers a distinct ad-




Figure 3. A) Quantity of Diacetyl produced by pGIT-d-LAB isolates, B) heatmap of the peak value.




Figure 4. A) Quantity of Lactic Acid produced by pGIT-d-LAB isolates, B) heatmap of the peak value.




Figure 5. A) Quantity of H₂O₂ produced by pGIT-d-LAB isolates, B) heatmap of the peak value.

vantage to explore novel probiotic strains. Consequently, the necessity to cultivate host-specific probiotics to attain optimal health advantages and enhance livestock performance becomes paramount. This study aimed to evaluate the prophylactic potential of a LAB from poultry against common pathogenic organisms. The application of probiotics in the poultry industry as suitable alternative to antibiotics performance has garnered significant interest in contemporary times. Beyond the myriad advantageous attributes of probiotics, the extraction of probiotic strains from their indigenous hosts stands as the foremost choice. Microbial strains sourced from their natural habitat possess an inherent familiarity with the gastrointestinal tract, thereby enabling them to naturally propagate and more effectively manifest the desired advantageous outcomes, surpassing strains obtained from alternative sources. It was interesting to note that none of the antimicrobials produced by pGIT-d-LAB isolates showed inhibitory activity against the organism producing it.

According to our findings, we concluded that the rise in lactic acid production over time is attributed to a decrease in pH, facilitating the growth of LAB at the expense of other competing organisms. This is in conformity with reports from other studies^{6,9}. The antimicrobial impact of lactic acid arises from its non-ionized state, which facilitates its penetration through membranes. Subsequently, within the cytoplasm, it releases hydrogen ions, thereby impeding essential cellular functions which will eventually lead to death. Additionally, we believe that the efficacy and action of pGIT-d-LAB against pathogenic micro-organisms in this study was based on the action of H₂O₂, lactic acid, bacteriocins, diacetyl and a combination of various uncharacterized antimicrobial molecules released into the cellular milieu of the offending microorganisms. Our observational study aligns with the findings reported by other researchers^{17,20,38}. However, the CFS of *L. fermentum* did not demonstrate inhibitory effects on *Candida* spp. examined. This result sharply contrasts with the findings of Ronnqvist *et al*⁴⁶, who reported the inhibitory activities of *Lactobacillus* spp. against *Candida* spp. Although showing great potential, the clinical utilization of LAB of poultry origin as probiotics in infection treatment demands more in-depth research, comprehensive clinical trials, and established protocols to substantiate their effectiveness and safety. These guidelines underscore the importance of meticulously planned investigations that can substantiate the efficiency and safety of LAB strains in managing infections. We understand that diverse strains of LAB exhibit distinct antimicrobial attributes, this has underscored the significance of discerning strains with superior efficacy against bacterial and fungal pathogens.

Conclusion

In conclusion, pGIT-d-LAB exhibit considerable potential as viable probiotics for addressing bacterial

and fungal infections in poultry. Their diverse array of mechanisms, encompassing the synthesis of antimicrobial agents such as lactic acid, H₂O₂ and immunomodulatory effects, positions them as compelling contenders for the management of microbial infections. Nevertheless, additional research is imperative to ascertain the most suitable strains, dosages, and delivery strategies, while also adhering to regulatory standards. Only through these endeavors can widespread clinical implementation be responsibly pursued.

Conflict of Interest

The authors declare that they have no competing interests.

References

1. Wang Y, Wu J, Lv M, Shao Z, Hungwe M, Wang J, et al. Metabolism characteristics of lactic acid Bacteria and the expanding applications in food industry. *Front Bioeng Biotechnol* 2021;9:612285.
2. Guo XH, Kim JM, Nam HM, Park SY, Kim JM. Screening lactic acid bacteria from swine origins for multistrain probiotics based on In vitro functional properties. *Anaerobe* 2010;16(4):321-6.
3. Al-Surrayai T, Al-Khalaifah H, Al-Mansour H, Kishk M, Al-Mutairi A, Sultan H, Al-Saleem H. Evaluation of the lactic acid bacteria based formulated probiotic product for poultry. *Front Anim Sci* 2022;3:1026958.
4. Tavakoli M, Hamidi-Esfahani Z, Hejazi MA, Azizi MH, Abbasi S. Characterization of probiotic abilities of lactobacilli isolated from Iranian koozeh traditional cheese. *Polish J Food Nutrition Sci* 2017;67(1):1.
5. Dvorožňáková E, Bucková B, Hurníková Z, Revajová V, Lauková A. Effect of probiotic bacteria on phagocytosis and respiratory burst activity of blood polymorphonuclear leukocytes (PMNL) in mice infected with *Trichinella spiralis*. *Vet Parasitol* 2016;231:69-76.
6. Adeniyi BA, Ayeni FA, Ogunbanwo ST. Antagonistic activities of lactic acid bacteria isolated from fermented dairy food against organisms implicated in urinary tract infection. *Biotechnology* 2006;5(2):183-8.
7. Biswas A, Dev K, Tyagi PK, Mandal A. The effect of multi strain probiotics as feed additives on performance, immunity, expression of nutrient transporter genes and gut morphometry in broiler chickens. *Anim Bioscience* 2022;35(1):64-74.
8. Toshimitsu T, Mochizuki J, Ikegami S, Itou H. Identification of a *Lactobacillus plantarum* strain that ameliorates chronic inflammation and metabolic disorders in obese and type 2 diabetic mice. *J Dairy Sci* 2016;99(2): 933-46.
9. Bamidele A, Adeniyi A. Evaluation of organic acids, anti-salmonella activities of lactic acid bacteria isolated from Nigerian grown salad vegetables. *British Biotechnology Journal* 2016;11(1):1-10.
10. Wang Y, Don, Z, Song D, Zhou H, Wang W, Miao H. Effects of microencapsulated probiotics and prebiotics on growth performance, antioxidative abilities, immune

- functions, and caecal microflora in broiler chickens. *Food Agric Immunol* 2018;29(1):859-69.
11. Yaqoob MU, Wang G, Wang M. An updated review on probiotics as an alternative of antibiotics in poultry. *Anim Biosci* 2022;35(8):1109-20.
 12. Reuben RC, Roy PC, Sarkar SL, Alam RU, Jahid IK. Isolation, characterization, and assessment of lactic acid bacteria toward their selection as poultry probiotics. *BMC Microbiol* 2019;19(1):253.
 13. Adetoye A, Pinloche E, Adeniyi BA, Ayeni FA. Characterization and anti-Salmonella activities of lactic acid bacteria isolated from cattle faeces. *BMC Microbiol* 2018;18(1):96.
 14. Liu A, Xu R, Zhang S, Wang Y, Hu B, Ao X, et al. Antifungal mechanisms and application of lactic acid bacteria in bakery products: A review. *Front Microbiol* 2022;13: 924398.
 15. Ahlberg SH, Joutsjoki V, Korhonen HJ. Potential of lactic acid bacteria in aflatoxin risk mitigation. *Int J Food Microbiol* 2015;207:87-102.
 16. Coda R, Cassone A, Rizzello CG, Nionelli L, Cardinali G, Gobetti M. Antifungal activity of *Wickerhamomyces anomalus* and *Lactobacillus plantarum* during sourdough fermentation: identification of novel compounds and long-term effect during storage of wheat bread. *Appl Environ Microbiol* 2011;77(10):3484-92.
 17. Mokoena MP, Omatola CA, Olaniran AO. Applications of lactic acid bacteria and their bacteriocins against food spoilage Microorganisms and foodborne pathogens. *Molecules* 2021;26(22):7055.
 18. López P, Spano G. Editorial: Industrial and health applications of lactic acid bacteria and their metabolites, volume II. *Front. Microbiol* 2023;14:1242253.
 19. Del Coco VF, Sparo MD, Sidoti A, Santín M, Basualdo JA, Córdoba MA. Effects of *Enterococcus faecalis* CECT 7121 on *Cryptosporidium parvum* infection in mice. *Parasitol Res* 2016 Aug;115(8):3239-44.
 20. Simons A, Alhanout K, Duval RE. Bacteriocins, antimicrobial peptides from bacterial origin: overview of their biology and their impact against multidrug-resistant bacteria. *Microorganisms* 2020;8(5):639.
 21. Hernández-González JC, Martínez-Tapia A, Lazcano-Hernández G, García-Pérez BE, Castrejón-Jiménez NS. Bacteriocins from lactic acid bacteria. A powerful alternative as antimicrobials, probiotics, and immunomodulators in veterinary medicine. *Animals (Basel)* 2021;11(4): 979.
 22. Zheng J, Gänzle MG, Lin XB, Ruan L, Sun M. Diversity and dynamics of bacteriocins from human microbiome. *Environ Microbiol* 2014;17(6):2133-43.
 23. Mokoena MP. Lactic acid bacteria and their bacteriocins: classification, biosynthesis and applications against uropathogens: A mini-review. *Molecules* 2017;22(8):1255.
 24. Ahlberg SH, Joutsjoki V, Korhonen HJ. Potential of lactic acid bacteria in aflatoxin risk mitigation. *Int J Food Microbiol* 2015;207:87-102.
 25. Cizeikiene D, Juodeikiene G, Paskevicius A, Bartkiene E. Antimicrobial activity of lactic acid bacteria against pathogenic and spoilage microorganism isolated from food and their control in wheat bread. *Food Control* 2013;31(2):539-45.
 26. Ebrahimi M, Sadeghi A, Mortazavi SA. The use of cyclic dipeptide producing LAB with potent anti-aflatoxigenic capability to improve techno-functional properties of clean-label bread. *Ann. Microbiol* 2020;70:24.
 27. Jin J, Nguyen TTH, Humayun S, Park S, Oh H, Lim S. Characteristics of sourdough bread fermented with *Pediococcus pentosaceus* and *Saccharomyces cerevisiae* and its bio-preservative effect against *Aspergillus flavus*. *Food Chem* 2012;345:128787.
 28. Moradi M, Guimarães JT, Sahin S. Current applications of exopolysaccharides from lactic acid bacteria in the development of food active edible packaging. *Curr Opin Food Sci* 2021;40:33-9.
 29. Cong L, Chen C, Mao S, Han Z, Zhu Z, Li Y. Intestinal bacteria, a powerful weapon for fungal infections treatment. *Front Cell Infect Microbiol* 2023;13:1187831.
 30. Ceresa C, Rinaldi M, Chiono V, Carmagnola I, Allegrone G, Fracchia L. Lipopeptides from *Bacillus subtilis* AC7 inhibit adhesion and biofilm formation of *Candida albicans* on silicone. *Antonie Van Leeuwenhoek* 2016; 109(10):1375-88.
 31. Rusu E, Enache G, Cursaru R, Alexescu A, Radu R, Onila O, et al. Prebiotics and probiotics in atopic dermatitis (Review). *Exp Therapeut Med* 2019;18(2):926-31.
 32. Steiner NC, Lorentz A. Probiotic potential of *Lactobacillus* species in allergic rhinitis. *Int Arch Allergy Immunol* 2021;182(9):807-18.
 33. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. *Cochrane Database Syst Rev* 2004;(2):CD003048.
 34. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. *Lett Appl Microbiol* 2007;45(4):454-60.
 35. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Am J Gastroenterol* 2009;104(4):1033-49.
 36. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. *J Gastroenterol Hepatol* 2007;22(8):1199-204.
 37. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA. Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut* 2005;54(2): 242-9.
 38. Shen YL, Zhang LQ, Yang Y, Yin BC, Ye BC, Zhou Y. Advances in role and mechanism of lactic acid bacteria in treating obesity. *Food Bioeng* 2022;1(8):101-15.
 39. Teng Y, Wang Y, Tian Y, Chen Y, Guan W, Piao C, et al. *Lactobacillus plantarum* LP104 ameliorates hyperlipidemia induced by AMPK pathways in C57BL/6N mice fed high-fat diet. *J Func Foods* 2020;64:103665.

40. JoVE Science Education Database, Microbiology. Serial Dilutions and Plating: Microbial Enumeration. JoVE, Cambridge, MA, (2023).
41. Nugroho ADW, Kleerebezem M, Bachmann H. A novel method for long-term analysis of lactic acid and ammonium production in non-growing *Lactococcus lactis* reveals pre-culture and strain dependence. *Front Bioeng Biotechnol* 2020 Oct 8;8:580090.
42. Seki M, Iida K, Saito M, Nakayama H, Yoshida S. Hydrogen peroxide production in *Streptococcus pyogenes*: involvement of lactate oxidase and coupling with aerobic utilization of lactate. *J Bacteriol.* 2004 Apr;186(7):2046-51.
43. Rosca I, Petrovici AR, Brebu M, Stoica I, Minea B, Marangoci N. An original method for producing acetaldehyde and diacetyl by yeast fermentation. *Braz J Microbiol* 2016;47(4):949-54.
44. Hayden DH, Karla AV, and Lixin Z. A review of antimicrobial resistance in poultry farming within low-resource settings. *Animals (Basel)* 2020;10(8):1264.
45. Przemysław R, Michał M, Hanna B, Sebastian N, Jarosław W, Danuta W, et al. Prevalence and characterization of antimicrobial resistance genes and class 1 and 2 integrons in multi-resistant *E. coli* isolated from poultry production. *Scientific Reports* 2022;12(1):6062.
46. Rönqvist D, Forsgren-Brusk U, Husmark U, Grahns-Håkansson E. *Lactobacillus fermentum* Ess-1 with unique growth inhibition of vulvo-vaginal candidiasis pathogens. *J Med Microbiol* 2007;56(Pt 11):1500-4.